Table 4.
Univariable regression analysis results; OR = ddds ratio, ITBL = ischemic type biliary lesions, IQR = interquartile range, CI = confidence interval.
| Characteristic | No Infectious Complication (n = 239) |
Infectious Complication (n = 46) | OR (CI) | p-Value |
|---|---|---|---|---|
| Age at the time of ERCP, median (min./max.) | 56 (21/77) | 58 (22/71) | 1.01 (0.98–1.04) | 0.68 |
| Sex, male, absolute (%) | 166 (69.5) | 44 (95.7) | 9.62 (2.27–40.7) | 0.002 |
| Period from transplant to ERCP, months, median (min./max.) | 18 (1/226) | 14.5 (0/115) | 0.99 (0.98–1.00) | 0.14 |
| Biliodigestive Anastomosis, absolute (%) | 15 (6.3) | 0 (0) | 0.00 (0.00) | 0.99 |
| Immunosuppressive agent, absolute (%) | ||||
| Cellcept | 138 (57.7) | 25 (54.3) | 0.87 (0.46–1.64) | 0.67 |
| Tacrolimus | 202 (84.5) | 35 (76.1) | 0.58 (0.27–1.25) | 0.16 |
| Prednisolone | 17 (7.1) | 9 (19.6) | 3.18 (1.32–7.66) | 0.01 |
| Cyclosporine | 20 (8.4) | 4 (8.7) | 1.04 (0.34–3.21) | 0.94 |
| Sirolimus | 12 (5.0) | 2 (4.3) | 0.86 (0.19–3.98) | 0.85 |
| Everolimus | 64 (26.8) | 13 (28.3) | 1.08 (0.53–2.18) | 0.84 |
| Number of immunosuppressive agents, absolute (%) | ||||
| 1 immunosuppressive agent | 32 (13.4) | 9 (19.6) | reference variable | |
| 2 immunosuppressive agents | 198 (82.8) | 33 (71.7) | 0.59 (0.26–1.35) | 0.22 |
| 3 immunosuppressive agents | 9 (3.8) | 4 (8.7) | 1.58 (0.39–6.35) | 0.52 |
| ERCP findings, absolute (%) | ||||
| Single anastomosis stenosis | 159 (66.5) | 16 (34.8) | reference variable | |
| ITBL | 75 (31.4) | 28 (60.9) | 3.71 (1.89–7.27) | <0.001 |
| Choledocholithiasis (stone-free after intervention) | 5 (2.1) | 2 (4.3) | 3.98 (0.71–22.17) | 0.12 |
| ERCP intervention, absolute (%) | ||||
| Sphincterotomy | 65 (27.2) | 16 (34.8) | 1.43 (0.73–2.79) | 0.30 |
| Dilatation | 218 (91.2) | 43 (93.5) | 1.38 (0.39–4.83) | 0.62 |
| Cholangioscopy | 26 (10.9) | 12 (26.1) | 2.89 (1.33–6.27) | 0.007 |
| Main bile duct stenting | 35 (14.6) | 7 (15.2) | 1.05 (0.43–2.52) | 0.92 |
| Usage of Dormia basket | 30 (12.6) | 9 (19.6) | 1.70 (0.74–3.86) | 0.21 |
| Periprocedural anti-infective therapy, absolute (%) | 239 (100) | 46 (100) | n.d. | n.d. |
| MDR colonization at the time of ERCP | 90 (37.7) | 20 (43.5) | 1.28 (0.67–2.41) | 0.46 |
| Delayed application of prophylactic anti-infective therapy >1 h after ERCP | 74 (31) | 23 (50) | 2.23 (1.18–4.23) | 0.01 |
| CRP after ERCP (mg/dL), median (IQR) | 0.95 (0.5–2.7) | 6.55 (3.9–10.0) | n.d. | <0.001 |
| Leucocytes after ERCP (Tsd/μL), median (IQR) | 4.95 (3.4–7.2) | 6.27 (3.8–8.8) | n.d. | <0.001 |
| Length of hospital stay, days, median (IQR) | 4 (3–5) | 5 (4–7) | n.d. | 0.003 |